For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
35
views
0
references
 Top references
cited by
734
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

      Author(s):
      Publication date:
      Journal: The New England journal of medicine
      Publisher: Massachusetts Medical Society

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.

          Related collections

          Author and article information

          Journal
          PubMed ID:: 21526923
          PMC ID:: 3157322
          DOI:: 10.1056/NEJMoa1102673

          Data availability:

          Comments

          Comment on this article

          scite_